DK0645376T3 - Substituerede 1-phenyl-oxazolin-2-on-derivater, fremstilling deraf og anvendelse som adhæsionsreceptor-antagonister - Google Patents

Substituerede 1-phenyl-oxazolin-2-on-derivater, fremstilling deraf og anvendelse som adhæsionsreceptor-antagonister

Info

Publication number
DK0645376T3
DK0645376T3 DK94114519T DK94114519T DK0645376T3 DK 0645376 T3 DK0645376 T3 DK 0645376T3 DK 94114519 T DK94114519 T DK 94114519T DK 94114519 T DK94114519 T DK 94114519T DK 0645376 T3 DK0645376 T3 DK 0645376T3
Authority
DK
Denmark
Prior art keywords
derivatives
substituted
phenyl
oxazolin
preparation
Prior art date
Application number
DK94114519T
Other languages
Danish (da)
English (en)
Inventor
Joachim Prof Dr Gante
Horst Dr Juraszyk
Peter Dr Raddatz
Hanns Dr Wurziger
Guido Melzer
Sabine Dr Bernotat-Danielowski
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of DK0645376T3 publication Critical patent/DK0645376T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK94114519T 1993-09-23 1994-09-15 Substituerede 1-phenyl-oxazolin-2-on-derivater, fremstilling deraf og anvendelse som adhæsionsreceptor-antagonister DK0645376T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4332384A DE4332384A1 (de) 1993-09-23 1993-09-23 Adhäsionsrezeptor-Antagonisten III

Publications (1)

Publication Number Publication Date
DK0645376T3 true DK0645376T3 (da) 1999-10-18

Family

ID=6498425

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94114519T DK0645376T3 (da) 1993-09-23 1994-09-15 Substituerede 1-phenyl-oxazolin-2-on-derivater, fremstilling deraf og anvendelse som adhæsionsreceptor-antagonister

Country Status (21)

Country Link
US (3) US5561148A (pl)
EP (1) EP0645376B1 (pl)
JP (1) JPH07179441A (pl)
KR (1) KR100347849B1 (pl)
CN (1) CN1052227C (pl)
AT (1) ATE178599T1 (pl)
AU (1) AU682050B2 (pl)
CA (1) CA2132579A1 (pl)
CZ (1) CZ288819B6 (pl)
DE (2) DE4332384A1 (pl)
DK (1) DK0645376T3 (pl)
ES (1) ES2132295T3 (pl)
GR (1) GR3030512T3 (pl)
HU (1) HU217980B (pl)
NO (1) NO305203B1 (pl)
PL (1) PL180462B1 (pl)
RU (1) RU2125560C1 (pl)
SK (1) SK282134B6 (pl)
TW (1) TW381086B (pl)
UA (1) UA40590C2 (pl)
ZA (1) ZA947405B (pl)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4313411A1 (de) * 1993-04-23 1994-10-27 Basf Ag 3-Halogen-3-hetarylcarbonsäurederivate, Verfahren und Zwischenprodukte zu ihrer Herstellung
DE4332384A1 (de) * 1993-09-23 1995-03-30 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten III
DE4429461A1 (de) * 1994-08-19 1996-02-22 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
DK0710657T3 (da) * 1994-11-02 1999-05-25 Merck Patent Gmbh Adhæsionsreceptor-antagonister
DE4439846A1 (de) * 1994-11-08 1996-05-09 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
ATE205205T1 (de) * 1995-02-03 2001-09-15 Upjohn Co Durch hetero-aromatische ring substituierte phenyloxazolidinone als antimikrobielles mittel
DE19516483A1 (de) * 1995-05-05 1996-11-07 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
DE19524765A1 (de) * 1995-07-07 1997-01-09 Boehringer Mannheim Gmbh Neue Oxazolidinonderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19601264A1 (de) * 1996-01-16 1997-07-17 Bayer Ag Pyrido-annellierte Thienyl- und Furanyl-Oxazolidinone
DE19601265A1 (de) * 1996-01-16 1997-07-17 Bayer Ag 2-Oxo- und 2-Thio-1,2-dihydrochinolinyl-oxazolidinone
DE19601627A1 (de) * 1996-01-18 1997-07-24 Bayer Ag Heteroatomhaltige Cyclopentanopyridyl-Oxazolidinone
DE19604223A1 (de) * 1996-02-06 1997-08-07 Bayer Ag Neue substituierte Oxazolidinone
HRP970049A2 (en) * 1996-02-06 1998-04-30 Bayer Ag New heteroaryl oxazolidinones
NZ333904A (en) * 1996-07-25 2000-06-23 Biogen Inc VLA-4 and IIb/IIIa cell adhesion inhibitors
EP0928194A4 (en) * 1996-08-29 2001-01-17 Merck & Co Inc COMPOSITIONS AND METHODS FOR ADMINISTRATING ANTAGONISTS OF THE INTEGRIN RECEPTOR
GB9812019D0 (en) * 1998-06-05 1998-07-29 Zeneca Ltd Chemical compounds
WO1999064417A2 (en) * 1998-06-05 1999-12-16 Astrazeneca Ab Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them
AU2592600A (en) 1998-12-23 2000-07-31 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
GB9928568D0 (en) 1999-12-03 2000-02-02 Zeneca Ltd Chemical compounds
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
GB0009803D0 (en) * 2000-04-25 2000-06-07 Astrazeneca Ab Chemical compounds
DE10129725A1 (de) 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
DE10159453A1 (de) * 2001-12-04 2003-06-18 Merck Patent Gmbh Verwendung von 1-Phenyl-oxazolidin-2-on-Verbindungen als Protease
US7141588B2 (en) * 2002-02-25 2006-11-28 Pfizer, Inc. N-aryl-2-oxazolidinone-5-carboxamides and their derivatives
CN1653064A (zh) * 2002-02-28 2005-08-10 阿斯特拉曾尼卡有限公司 噁唑烷酮衍生物、其制备方法以及包含它们的药用组合物
DE10300111A1 (de) * 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
EP1789096A4 (en) 2004-09-07 2009-07-08 Archemix Corp APTAMERS FOR THE VON WILLEBRAND FACTOR AND ITS USE AS THERAPEUTICS FOR THROMBOTIC DISEASES
KR20070101226A (ko) * 2004-09-07 2007-10-16 아케믹스 코포레이션 앱타머의 약화학
US7566701B2 (en) * 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
EP1685841A1 (en) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
DE102005045518A1 (de) 2005-09-23 2007-03-29 Bayer Healthcare Ag 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
DE102005047561A1 (de) 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
CA2624310C (en) 2005-10-04 2014-01-07 Bayer Healthcare Ag Polymorphic form of 5-chloro-n-({5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide
DE102005047558A1 (de) * 2005-10-04 2008-02-07 Bayer Healthcare Ag Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen
DE102006051625A1 (de) * 2006-11-02 2008-05-08 Bayer Materialscience Ag Kombinationstherapie substituierter Oxazolidinone
WO2008150495A2 (en) * 2007-06-01 2008-12-11 Archemix Corp. Vwf aptamer formulations and methods for use
EP2222636B1 (en) 2007-12-21 2013-04-10 Ligand Pharmaceuticals Inc. Selective androgen receptor modulators (sarms) and uses thereof
AU2009206658A1 (en) * 2008-01-24 2009-07-30 Merck Sharp & Dohme Corp. 3,5-substituted-1,3-oxazolidin-2-one derivatives
ES2864079T3 (es) 2014-05-30 2021-10-13 Pfizer Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos
WO2020214834A1 (en) 2019-04-19 2020-10-22 Ligand Pharmaceuticals Inc. Crystalline forms and methods of producing crystalline forms of a compound
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE791501A (fr) * 1971-11-19 1973-05-17 Albert Ag Chem Werke Diamines cycliques n,n'-disubstituees et leur procede de preparation
US4062862A (en) * 1975-07-04 1977-12-13 Nippon Chemiphar Co., Ltd. 5-Benzyl-2-oxazolidone derivatives and a process for producing the same
US4602093A (en) * 1984-02-08 1986-07-22 Merck & Co., Inc. Novel substituted imidazoles, their preparation and use
DE3723797A1 (de) * 1987-07-18 1989-01-26 Merck Patent Gmbh Oxazolidinone
CA1320730C (en) * 1987-10-16 1993-07-27 The Du Pont Merck Pharmaceutical Company Aminomethyl oxooxazolidinyl aroylbenzene derivatives useful as antibacterial agents
US5053393A (en) * 1988-07-20 1991-10-01 Monsanto Company Novel platelet-aggregation inhibitor
US5084466A (en) * 1989-01-31 1992-01-28 Hoffmann-La Roche Inc. Novel carboxamide pyridine compounds which have useful pharmaceutical utility
DE4005371A1 (de) * 1990-02-21 1991-08-22 Merck Patent Gmbh Oxazolidinone
DE4017211A1 (de) * 1990-05-29 1991-12-05 Merck Patent Gmbh Oxazolidinone
KR0146931B1 (ko) * 1992-04-30 1998-08-17 고바야시 유끼오 옥사졸리딘 유도체 및 그의 약학적으로 허용가능한 염
US5532225A (en) * 1992-07-31 1996-07-02 Sri International Acyclic purine phosphonate nucleotide analogs as antiviral agents, and related synthetic methods
DK0623615T3 (da) * 1993-05-01 1999-12-13 Merck Patent Gmbh Adhæsionsreceptor-antagonister
IL109570A0 (en) * 1993-05-17 1994-08-26 Fujisawa Pharmaceutical Co Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
DE4324393A1 (de) * 1993-07-21 1995-01-26 Merck Patent Gmbh 4-Aryloxy- und 4-Arylthiopiperidinderivate
DE4332384A1 (de) * 1993-09-23 1995-03-30 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten III
TW286317B (pl) * 1993-12-13 1996-09-21 Hoffmann La Roche
DE4439846A1 (de) * 1994-11-08 1996-05-09 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
TW363051B (en) * 1995-08-31 1999-07-01 Mitsui Toatsu Chemicals Substituted amidine derivatives and platelet aggregation inhibitor containing the same

Also Published As

Publication number Publication date
CZ288819B6 (cs) 2001-09-12
PL180462B1 (pl) 2001-02-28
US5723480A (en) 1998-03-03
ES2132295T3 (es) 1999-08-16
EP0645376A1 (de) 1995-03-29
NO943523D0 (no) 1994-09-22
JPH07179441A (ja) 1995-07-18
KR100347849B1 (ko) 2002-11-16
HU9402724D0 (en) 1994-12-28
SK112194A3 (en) 1995-05-10
AU682050B2 (en) 1997-09-18
US5561148A (en) 1996-10-01
RU2125560C1 (ru) 1999-01-27
DE4332384A1 (de) 1995-03-30
RU94034124A (ru) 1996-07-10
ATE178599T1 (de) 1999-04-15
AU7305094A (en) 1995-04-06
HU217980B (hu) 2000-05-28
KR950008493A (ko) 1995-04-17
SK282134B6 (sk) 2001-11-06
TW381086B (en) 2000-02-01
PL305144A1 (en) 1995-04-03
ZA947405B (en) 1995-05-15
US6028090A (en) 2000-02-22
GR3030512T3 (en) 1999-10-29
CN1106806A (zh) 1995-08-16
UA40590C2 (uk) 2001-08-15
CN1052227C (zh) 2000-05-10
HUT71233A (en) 1995-11-28
NO305203B1 (no) 1999-04-19
DE59408068D1 (de) 1999-05-12
EP0645376B1 (de) 1999-04-07
NO943523L (no) 1995-03-24
CA2132579A1 (en) 1995-03-24
CZ224794A3 (en) 1995-07-12

Similar Documents

Publication Publication Date Title
DK0645376T3 (da) Substituerede 1-phenyl-oxazolin-2-on-derivater, fremstilling deraf og anvendelse som adhæsionsreceptor-antagonister
DK0623615T3 (da) Adhæsionsreceptor-antagonister
DK0381033T3 (da) Carboxylsyre- og sulfonsyreamider
CA2014379A1 (en) Compounds
ATE139778T1 (de) Xanthinverbindungen
DK0608759T3 (da) Piperazinderivater
ATE96030T1 (de) Cholesterolvermindernde wirkstoffe.
ATE69444T1 (de) N-substituierte-n-nitroso-aminoacetonitrile, verfahren zu ihrer herstellung und ihre verwendung.
ATE36325T1 (de) Derivate von 5-halovinyl-2'-deoxyuridin.
DK0544171T3 (da) Anvendelse af 5,6-dihydro-dibenz(b,e)azepin-6,11-dion-11-oximer til fremstilling af antiretrovirale midler
UA41280C2 (uk) Оксазолідинони, їх солі, спосіб їх одержання, фармацевтичний препарат та спосіб його одержання
FI943360L (fi) Propoksibentseenijohdannaisia